IL6 and breast cancer: The pharmacologically use of neutralizing antibodies targeting IL-6 (Tocilizumab) and IL-8 (Reparixin) receptors has been shown to significantly reduce metastasis to the lungs, liver, and lymph nodes in preclinical BC models [197].